1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
China Isotope & Radiation Corp.

China Isotope & Radiation Corp.

1.28
EUR
0.00
(0.00%)
594.97MMarket Cap
Mar 31Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.73
7.39
11.14
11.64
12.47
13.36
16.08
19.24
20.74
23.68
22.47
- -
Basic EPS, GAAP
0.79
0.82
1.13
1.15
1.03
0.67
1.05
1.23
1.16
1.27
1.02
- -
Free Cash Flow per Basic Share
1.22
1.43
1.79
2.06
1.88
0.91
2.48
2.7
0.27
0.45
1.68
- -
Dividend per Share
- -
1
0.74
0.32
0.31
0.14
0.18
0.38
0.44
0.39
0.39
- -
Book Value per Share
2.65
2.9
5.84
10.95
11.75
12.16
13.07
13.97
14.67
15.65
16.34
16.6
Tangible Book Value per Share
2.47
2.66
5.72
10.42
11.28
11.56
12.45
13.37
13.75
14.39
14.7
13.7
Basic Weighted Avg Shares
320
320
240
279
320
320
320
320
320
320
320
320
Sales/Revenue/Turnover
2,152
2,363
2,672
3,250
3,989
4,274
5,144
6,154
6,635
7,575
7,188
- -
Operating Margin (%)
20.8
20.36
18.97
18.28
16.06
13.87
14.42
14.56
12.13
14.59
14.59
- -
Depreciation Expense
54
65
68
74
132
172
197
223
264
245
265
- -
Net Income, GAAP
254
262
271
322
329
214
336
392
371
407
327
- -
Effective Tax Rate (%)
15.53
15.26
14.75
15.23
14.84
20.24
16.15
17.98
15.86
15.85
33.82
- -
Profit Margin (%)
11.81
11.09
10.16
9.91
8.25
5
6.53
6.37
5.59
5.37
4.56
- -
Working Capital
704
622
1,544
2,692
2,711
2,999
2,642
3,512
3,941
3,895
4,045
4,259
LT Debt
60
- -
150
150
655
630
185
838
1,478
1,601
1,802
1,942
Total Equity
1,354
1,473
2,446
4,338
5,003
5,506
6,034
6,610
7,139
7,745
8,133
8,348
Return on Invested Capital (%)
- -
24.08
19.14
15.66
11.53
7.92
9.77
10.2
9.48
9.38
6.5
- -
Return on Capital (%)
- -
6
3.22
1.78
0.95
-0.34
0.43
0.81
-0.05
-0.27
0.32
- -
Return on Common Equity (%)
- -
29.53
19.41
11.99
9.06
5.58
8.32
9.07
8.1
8.39
6.4
- -

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
1,222
924
921
LT Borrowings
1,752
1,747
1,896
LT Finance Leases
46
55
46
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
320
320
320
Market Capitalization
- -
5,521
4,612

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
9,638
9,336
9,555
Cash, Cash Equivalents & STI
2,693
2,565
2,554
Accounts Receivable, Net
4,993
4,843
- -
Inventories
1,423
1,347
1,523
Total Current Liabilities
5,445
5,291
5,296
Payables & Accruals
- -
- -
- -
ST Debt
1,222
924
921
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.82%
8.13%
5.02%
Free Cash Flow
43.45%
87.23%
277.83%
Net Income, GAAP
5.11%
11.75%
-19.48%
Sales/Revenue/Turnover
13.12%
11.37%
-5.11%
Total Cash Common Dividend
- -
28.92%
1.09%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
7,575
2025
- -
- -
7,188
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.27
2025
- -
- -
1.02
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.39
2025
- -
- -
0.39
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Peng Hui Li
Full Time Employees
3,578
Sector
Health technology
Industry
Medical specialties
Address
No. 66 Changwa Middle Street Beijing BE China 100000
IPO Date
Jul 6, 2018
Website
china-isotope.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
China Isotope & Radiation Corporation (CIRC), a holding subsidiary of China National Nuclear Corporation founded in 1983 and headquartered in Beijing, China, ranks as China's largest comprehensive nuclear enterprise focused on the research, development, manufacture, distribution, and service of radioisotope and radiation technology products; its core offerings encompass over 70 nuclides and 300 products across radioisotope preparation via nuclear reactors and cyclotrons, diagnostic and therapeutic radiopharmaceuticals including 99Mo-99mTc generators and 99mTc kits, radioactive sources, radiation engineering solutions such as nuclear reactors and cobalt-60 facilities, irradiation processing services for medical devices, food, and traditional Chinese medicines, in vivo therapy nuclides, radioimmunoassay kits, and [13C]/[14C]-urea breath test kits and instruments; operations span three radiopharmaceutical manufacturing and research bases in Beijing, Chengdu, and Shenzhen, with radiopharmacies in approximately 20 cities supporting a nationwide marketing and technical network, alongside exports of seven product categories to over 50 countries, primarily targeting healthcare, industrial, and research sectors in Asia and globally. CIRC maintains one of the world's widest ranges of isotope products and the most complete industrial chain in its field, positioning it as Asia's largest supplier of nuclear technology applications. In late November 2025, CIRC entered a strategic cooperation agreement with CNNC Capital Holdings Limited to collaborate on mergers and acquisitions, equity investments, and resource sharing for enhanced development in the nuclear sector; the company also received recognition for its ESG practices, winning the Outstanding China ESG Practice (2025) award and inclusion in the ESG Pioneers Index (Top 100) by Central China Securities.